Alzchem Group AG and Crearene AG, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis. Dialysis is a treatment method which is applied for patients with a compromised kidney function, and which removes toxins, waste substances and salts from the blood.
Market Closed -
Other stock markets
|
After market 18:58:00 | |||
43.3 EUR | -3.35% | 42.9 | -0.92% |
04-30 | Transcript : AlzChem Group AG, Q1 2024 Earnings Call, Apr 30, 2024 | |
04-30 | AlzChem Group AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.54% | 490M | |
-2.06% | 73.82B | |
+2.17% | 47.49B | |
+2.16% | 32.7B | |
+4.50% | 17.15B | |
-6.71% | 11.92B | |
+12.42% | 11.85B | |
+0.37% | 10.66B | |
+9.00% | 9.76B | |
-7.59% | 8.31B |
- Stock Market
- Equities
- ACT Stock
- News AlzChem Group AG
- Alzchem and Crearene Develop Treatments for the Dialysis Market